Orion's dexdor sedative gets European approval
This article was originally published in Scrip
Executive Summary
The European Commission has granted Orion's dexdor (dexmedetomidine) centralised approval covering 27 European Union countries, with the company planning to begin a European roll-out in Germany and Austria in early 2012. It will launch much later in other European countries.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.